ABOS Files Form 8-K Furnishing Earnings Release and Presentation

Rhea-AI Filing Summary

Acumen Pharmaceuticals reported that it has furnished an earnings press release and posted an updated investor presentation that reflects the companys cash, cash equivalents and marketable securities balance as of June 30, 2025. The filing states these materials are furnished as Exhibits 99.1 and 99.2 and explicitly notes that the furnished information is not being "filed" under the Exchange Act and is not incorporated by reference in other securities filings.

The Form 8-K does not include numeric financial results within the filing itself; instead it directs readers to the furnished press release and presentation for details. The company also states that the submission is not an admission as to materiality of any Regulation FD disclosures.

Positive

• Furnished an earnings press release (Exhibit 99.1)
• Posted an updated corporate presentation reflecting cash, cash equivalents and marketable securities as of June 30, 2025 (Exhibit 99.2)
• Explicitly clarifies exhibits are furnished and not "filed," limiting Section 18 liabilities

Negative

• The Form 8-K does not include numeric financial results or cash amounts; investors must consult the exhibits for details
• Furnished exhibits are not incorporated by reference in other filings, limiting the Form 8-K's standalone informativeness

Insights

Financial Analyst

TL;DR: Routine Form 8-K furnishing earnings release and updated presentation; no financial figures included in the filing itself.

The filing notifies investors that Acumen has furnished an earnings press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) which reflects the company's cash, cash equivalents and marketable securities balance as of June 30, 2025. Because the filing itself does not disclose numerical results or performance metrics, investors must review the exhibits to assess financial performance. The filing's explicit statement that the exhibits are "furnished" and not "filed" limits statutory liabilities tied to Section 18.

Corporate Governance Expert

TL;DR: Disclosure complies with Regulation FD formatting; materiality is left to the included exhibits rather than the Form 8-K text.

The Form 8-K follows standard practice by furnishing an earnings press release and updating an investor presentation while clarifying the exhibits are furnished, not filed. The company also disclaims that the submission is not an admission of materiality. From a governance perspective, this is a formal and transparent route to disseminate information, but the absence of numeric data in the filing means the Form 8-K alone does not allow assessment of financial or operational impact.

0001576885FALSE1210-1220 Washington StreetSuite 210NewtonMassachusetts00015768852025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________________

FORM 8-K

____________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 12, 2025

____________________________

Acumen Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

____________________________

Delaware			001-40551			36-4108129
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

1210-1220 Washington Street, Suite 210 Newton, Massachusetts			02465
(Address of Principal Executive Offices)			(Zip Code)

(617) 344-4190

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

____________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value

ABOS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, Acumen Pharmaceuticals, Inc. (the “Company”) reported financial results and business highlights for the quarter ended June 30, 2025. A copy of this press release (the “Earnings Press Release”) is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”) and is incorporated by reference.

The information in this Item 2.02 of this Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 7.01     Regulation FD Disclosure.

On August 12, 2025, the Company posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/presentations, which the Company may use from time to time in communications or conferences. The corporate presentation was updated to reflect the Company’s cash, cash equivalents and marketable securities balance as of June 30, 2025. A copy of the corporate presentation is attached as Exhibit 99.2 to this Report.

The information in this Item 7.01 of this Report (including Exhibit 99.2), is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company’s submission of this Report shall not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01    Financial Statements and Exhibits.

(d).Exhibits

Exhibit No.						Description
99.1						Earnings Press Release, dated August 12, 2025
99.2						Corporate Presentation, dated August 12, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Acumen Pharmaceuticals, Inc.
Dated: August 12, 2025			By:			/s/ Matthew Zuga
						Matthew Zuga Chief Financial Officer and Chief Business Officer

FAQ

What did Acumen Pharmaceuticals (ABOS) file on this Form 8-K?

The company furnished an earnings press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) reflecting cash, cash equivalents and marketable securities as of June 30, 2025.

Are the exhibits in ABOSs 8-K considered "filed" with the SEC?

No. The Form 8-K states the press release and presentation are furnished and explicitly are not being deemed "filed" for purposes of Section 18 of the Exchange Act.

Does the Form 8-K disclose the amount of cash or marketable securities?

No. The Form 8-K notes the presentation reflects the balance as of June 30, 2025 but the filing itself does not include numeric amounts.

Who signed the Form 8-K for ABOS?

The report was signed by Matthew Zuga, Chief Financial Officer and Chief Business Officer.

Does the company say the submission is an admission of materiality?

No. The company expressly states the submission shall not be deemed an admission as to the materiality of any information required to be disclosed for Regulation FD purposes.